Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent

Attila Nagy, Andrew V Schally, Patricia Armatis, Karoly Szepeshazi, Gabor Halmos, Magdolna Kovacs, Marta Zarandi, Kate Groot, Masahiro Miyazaki, Andreas Jungwirth, Judit Horvath

Research output: Contribution to journalArticle

181 Citations (Scopus)

Abstract

Doxorubicin (DOX) and its daunosamine-modified derivative, 2-pyrrolino- DOX, which is 500-1000 times more active than DOX, were incorporated into agonistic and antagonistic analogs of luteinizing hormone-releasing hormone (LH-RH). The conjugation of DOX with LH-RH analogs was performed by using N- (9-fluorenylmethoxycarbonyl)-DOX-14-O-hemiglutarate, a dicarboxylic acid ester derivative of DOX. Coupling this derivative covalently to the ε-amino group of the D-Lys side chain of agonist [D-Lys6]LH-RH or antagonistic analog Ac-D-Nal(2)-D-Phe(4Cl)-D-Pal(3)-Ser-Tyr-D-Lys-Leu-Arg-Pro-D-Ala-NH2 [where Nal(2) = 3-(2-naphthyl)alanine, Pal(3) = 3-(3-pyridyl)alanine, and Phe(4Cl) = 4-chlorophenylalanine] was followed by the removal of the 9- fluorenylmethoxycarbonyl protective group to yield cytotoxic derivatives of LH-RH analogs containing DOX. From these DOX containing LH-RH hybrids, intensely potent analogs with daunosamine-modified derivatives of DOX can be readily formed. Thus, cytotoxic LH-RH agonist containing DOX (AN-152) can be converted in a 66% yield by a reaction with a 30-fold excess of 4- iodobutyraldehyde in N,N-dimethylformamide into a derivative having 2- pyrrolino-DOX (AN-207). Hybrid molecules AN-152 and AN-207 fully preserve the cytotoxic activity of their radicals, DOX or 2-pyrrolino-DOX, respectively, in vitro, and also retain the high binding affinity of the peptide hormone portion of the conjugates to rat pituitary receptors for LH-RH. These highly potent cytotoxic analogs of LH-RH were designed as targeted anti-cancer agents for the treatment of various tumors that possess receptors for the carrier peptide. Initial in vivo studies show that the hybrid molecules are much less toxic than the respective cytotoxic radicals incorporated and significantly more active in inhibiting tumor growth.

Original languageEnglish
Pages (from-to)7269-7273
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume93
Issue number14
DOIs
StatePublished - Jul 9 1996
Externally publishedYes

Fingerprint

Gonadotropin-Releasing Hormone
Doxorubicin
AN 204
Dimethylformamide
Neoplasms
Dicarboxylic Acids
Peptide Receptors
Peptide Hormones
Poisons
Esters

Keywords

  • antitumor activity
  • hybrid molecules
  • receptor binding
  • targeted chemotherapeutic agents

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. / Nagy, Attila; Schally, Andrew V; Armatis, Patricia; Szepeshazi, Karoly; Halmos, Gabor; Kovacs, Magdolna; Zarandi, Marta; Groot, Kate; Miyazaki, Masahiro; Jungwirth, Andreas; Horvath, Judit.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 93, No. 14, 09.07.1996, p. 7269-7273.

Research output: Contribution to journalArticle

Nagy, Attila ; Schally, Andrew V ; Armatis, Patricia ; Szepeshazi, Karoly ; Halmos, Gabor ; Kovacs, Magdolna ; Zarandi, Marta ; Groot, Kate ; Miyazaki, Masahiro ; Jungwirth, Andreas ; Horvath, Judit. / Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. In: Proceedings of the National Academy of Sciences of the United States of America. 1996 ; Vol. 93, No. 14. pp. 7269-7273.
@article{df707372eda34222b3a5818d131b4557,
title = "Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent",
abstract = "Doxorubicin (DOX) and its daunosamine-modified derivative, 2-pyrrolino- DOX, which is 500-1000 times more active than DOX, were incorporated into agonistic and antagonistic analogs of luteinizing hormone-releasing hormone (LH-RH). The conjugation of DOX with LH-RH analogs was performed by using N- (9-fluorenylmethoxycarbonyl)-DOX-14-O-hemiglutarate, a dicarboxylic acid ester derivative of DOX. Coupling this derivative covalently to the ε-amino group of the D-Lys side chain of agonist [D-Lys6]LH-RH or antagonistic analog Ac-D-Nal(2)-D-Phe(4Cl)-D-Pal(3)-Ser-Tyr-D-Lys-Leu-Arg-Pro-D-Ala-NH2 [where Nal(2) = 3-(2-naphthyl)alanine, Pal(3) = 3-(3-pyridyl)alanine, and Phe(4Cl) = 4-chlorophenylalanine] was followed by the removal of the 9- fluorenylmethoxycarbonyl protective group to yield cytotoxic derivatives of LH-RH analogs containing DOX. From these DOX containing LH-RH hybrids, intensely potent analogs with daunosamine-modified derivatives of DOX can be readily formed. Thus, cytotoxic LH-RH agonist containing DOX (AN-152) can be converted in a 66{\%} yield by a reaction with a 30-fold excess of 4- iodobutyraldehyde in N,N-dimethylformamide into a derivative having 2- pyrrolino-DOX (AN-207). Hybrid molecules AN-152 and AN-207 fully preserve the cytotoxic activity of their radicals, DOX or 2-pyrrolino-DOX, respectively, in vitro, and also retain the high binding affinity of the peptide hormone portion of the conjugates to rat pituitary receptors for LH-RH. These highly potent cytotoxic analogs of LH-RH were designed as targeted anti-cancer agents for the treatment of various tumors that possess receptors for the carrier peptide. Initial in vivo studies show that the hybrid molecules are much less toxic than the respective cytotoxic radicals incorporated and significantly more active in inhibiting tumor growth.",
keywords = "antitumor activity, hybrid molecules, receptor binding, targeted chemotherapeutic agents",
author = "Attila Nagy and Schally, {Andrew V} and Patricia Armatis and Karoly Szepeshazi and Gabor Halmos and Magdolna Kovacs and Marta Zarandi and Kate Groot and Masahiro Miyazaki and Andreas Jungwirth and Judit Horvath",
year = "1996",
month = "7",
day = "9",
doi = "10.1073/pnas.93.14.7269",
language = "English",
volume = "93",
pages = "7269--7273",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "14",

}

TY - JOUR

T1 - Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent

AU - Nagy, Attila

AU - Schally, Andrew V

AU - Armatis, Patricia

AU - Szepeshazi, Karoly

AU - Halmos, Gabor

AU - Kovacs, Magdolna

AU - Zarandi, Marta

AU - Groot, Kate

AU - Miyazaki, Masahiro

AU - Jungwirth, Andreas

AU - Horvath, Judit

PY - 1996/7/9

Y1 - 1996/7/9

N2 - Doxorubicin (DOX) and its daunosamine-modified derivative, 2-pyrrolino- DOX, which is 500-1000 times more active than DOX, were incorporated into agonistic and antagonistic analogs of luteinizing hormone-releasing hormone (LH-RH). The conjugation of DOX with LH-RH analogs was performed by using N- (9-fluorenylmethoxycarbonyl)-DOX-14-O-hemiglutarate, a dicarboxylic acid ester derivative of DOX. Coupling this derivative covalently to the ε-amino group of the D-Lys side chain of agonist [D-Lys6]LH-RH or antagonistic analog Ac-D-Nal(2)-D-Phe(4Cl)-D-Pal(3)-Ser-Tyr-D-Lys-Leu-Arg-Pro-D-Ala-NH2 [where Nal(2) = 3-(2-naphthyl)alanine, Pal(3) = 3-(3-pyridyl)alanine, and Phe(4Cl) = 4-chlorophenylalanine] was followed by the removal of the 9- fluorenylmethoxycarbonyl protective group to yield cytotoxic derivatives of LH-RH analogs containing DOX. From these DOX containing LH-RH hybrids, intensely potent analogs with daunosamine-modified derivatives of DOX can be readily formed. Thus, cytotoxic LH-RH agonist containing DOX (AN-152) can be converted in a 66% yield by a reaction with a 30-fold excess of 4- iodobutyraldehyde in N,N-dimethylformamide into a derivative having 2- pyrrolino-DOX (AN-207). Hybrid molecules AN-152 and AN-207 fully preserve the cytotoxic activity of their radicals, DOX or 2-pyrrolino-DOX, respectively, in vitro, and also retain the high binding affinity of the peptide hormone portion of the conjugates to rat pituitary receptors for LH-RH. These highly potent cytotoxic analogs of LH-RH were designed as targeted anti-cancer agents for the treatment of various tumors that possess receptors for the carrier peptide. Initial in vivo studies show that the hybrid molecules are much less toxic than the respective cytotoxic radicals incorporated and significantly more active in inhibiting tumor growth.

AB - Doxorubicin (DOX) and its daunosamine-modified derivative, 2-pyrrolino- DOX, which is 500-1000 times more active than DOX, were incorporated into agonistic and antagonistic analogs of luteinizing hormone-releasing hormone (LH-RH). The conjugation of DOX with LH-RH analogs was performed by using N- (9-fluorenylmethoxycarbonyl)-DOX-14-O-hemiglutarate, a dicarboxylic acid ester derivative of DOX. Coupling this derivative covalently to the ε-amino group of the D-Lys side chain of agonist [D-Lys6]LH-RH or antagonistic analog Ac-D-Nal(2)-D-Phe(4Cl)-D-Pal(3)-Ser-Tyr-D-Lys-Leu-Arg-Pro-D-Ala-NH2 [where Nal(2) = 3-(2-naphthyl)alanine, Pal(3) = 3-(3-pyridyl)alanine, and Phe(4Cl) = 4-chlorophenylalanine] was followed by the removal of the 9- fluorenylmethoxycarbonyl protective group to yield cytotoxic derivatives of LH-RH analogs containing DOX. From these DOX containing LH-RH hybrids, intensely potent analogs with daunosamine-modified derivatives of DOX can be readily formed. Thus, cytotoxic LH-RH agonist containing DOX (AN-152) can be converted in a 66% yield by a reaction with a 30-fold excess of 4- iodobutyraldehyde in N,N-dimethylformamide into a derivative having 2- pyrrolino-DOX (AN-207). Hybrid molecules AN-152 and AN-207 fully preserve the cytotoxic activity of their radicals, DOX or 2-pyrrolino-DOX, respectively, in vitro, and also retain the high binding affinity of the peptide hormone portion of the conjugates to rat pituitary receptors for LH-RH. These highly potent cytotoxic analogs of LH-RH were designed as targeted anti-cancer agents for the treatment of various tumors that possess receptors for the carrier peptide. Initial in vivo studies show that the hybrid molecules are much less toxic than the respective cytotoxic radicals incorporated and significantly more active in inhibiting tumor growth.

KW - antitumor activity

KW - hybrid molecules

KW - receptor binding

KW - targeted chemotherapeutic agents

UR - http://www.scopus.com/inward/record.url?scp=8944225497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8944225497&partnerID=8YFLogxK

U2 - 10.1073/pnas.93.14.7269

DO - 10.1073/pnas.93.14.7269

M3 - Article

C2 - 8692981

AN - SCOPUS:8944225497

VL - 93

SP - 7269

EP - 7273

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 14

ER -